Loading...

NSS

NSRX

NASUS PHARMA LTD

(NSRX)

2026 6-K

Business Update

25 Mar '26

Positive Clinical Data

16 Mar '26

Shareholder Meeting Results

6 Mar '26

Virtual Shareholder Meeting

4 Mar '26

Funding Announcement

13 Feb '26

Private Placement

11 Feb '26

Shareholder Meeting Notice

29 Jan '26

Positive Interim Results

20 Jan '26

Financial Report

29 Dec '25

CEO Shareholder Letter

22 Dec '25

Leadership Appointment

20 Nov '25

Clinical Trial Launch

18 Nov '25

Corporate Presentation Release

3 Nov '25

Collaboration Update

8 Oct '25

IPO Update

30 Sep '25

Board Changes

5 Sep '25

External Links:

SEC

On January 20, 2026, Nasus Pharma Ltd reported positive interim results from its Phase 2 clinical study of NS002, an intranasal epinephrine powder, and also updated its corporate presentation.

AI Assistant

NASUS PHARMA LTD

2026

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.